i'm really concerned about with the rise of crispers is the idea that this technology is not intensely difficult to use for a bad actor like this. This wouldn't be like, let's say, building an atomic bomb, where you'd have to build a lot of facilities around it,. We're talking about a cutting mechanism that's fairly accessible, that's going to be fairly accessible to a lot of people with scientific knowledge like that. i'd like to we live in a world now where there are no standards on germ line engineering. It happened in chinaa in a very controversial case. So when you say this could never happen, unfortunately, you know, it could.
Genetically edited humans are already here. Gene editing has massive implications for treating chronic illnesses and even the food we eat. So what does this mean for your investments and, y'know, possibly humanity? Ricky Mulvey talks with Motley Fool Advisor Karl Thiel about: - How CRISPR works - Some of the possibilities for CRISPR, from sickle cell cures to drought-resistant crops - How investors can approach investing in gene therapies - Biotech metrics to watch.
Companies mentioned: BLUE, CRSP, GILD, EDIT, VRTX, NTLA
Host: Ricky Mulvey Guest: Karl Theil Engineers: Tim Sparks, Dan Boyd
Learn more about your ad choices. Visit megaphone.fm/adchoices